What is Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals is a biopharmaceutical company dedicated to the research and development of precision medicines for rare genetic obesity disorders. The company's core focus lies in targeting the melanocortin-4 receptor (MC4R) pathway, which is implicated in diseases causing hyperphagia and severe obesity. Since its inception in 2008, Rhythm Pharmaceuticals has been committed to scientific exploration aimed at addressing the underlying causes of these rare conditions, thereby advancing therapeutic solutions for affected patients. Its operational footprint extends across North America and Europe, including France and the Netherlands, reflecting its international scope.
How much funding has Rhythm Pharmaceuticals raised?
Rhythm Pharmaceuticals has raised a total of $848.5M across 8 funding rounds:
Series A
$40M
Series B
$33M
Other Financing Round
$41M
Stock Offering
$138M
Stock Offering
$174M
Stock Offering
$172.5M
Debt
$100M
Series A
$150M
Series A (2010): $40M with participation from MPM Capital, New Enterprise Associates (NEA), and Third Rock Ventures
Series B (2012): $33M led by MPM Capital, Pfizer Venture Investments, Ipsen, Third Rock Ventures, and NEA
Other Financing Round (2017): $41M supported by Third Rock Ventures, NEA, Deerfield, MPM Capital, Pfizer Venture Investments, OrbiMed, and Ipsen
Stock Issuance/Offering (2017): $138M featuring Undisclosed
Stock Issuance/Offering (2018): $174M backed by Undisclosed
Stock Issuance/Offering (2019): $172.5M with participation from Undisclosed
Debt (2022): $100M led by HealthCare Royalty Partners
Series A (2024): $150M supported by Perceptive Advisors
Key Investors in Rhythm Pharmaceuticals
Perceptive Advisors
Perceptive Advisors is an investment firm founded in 1999, managing approximately $7 billion in assets and specializing in funding innovative healthcare and life sciences technologies.
HealthCare Royalty Partners
HealthCare Royalty Partners (HCRP) is a global healthcare investment firm primarily focused on investing in commercial-stage healthcare product assets, based in Stamford, Connecticut.
Third Rock Ventures
Third Rock Ventures is a healthcare venture firm established in 2007, dedicated to discovering, launching, and building companies that significantly impact people's lives through disruptive science and medicine.
What's next for Rhythm Pharmaceuticals?
The recent major strategic investment signals a pivotal phase for Rhythm Pharmaceuticals, likely enabling the company to accelerate its clinical development programs and expand its commercialization efforts for its novel obesity treatments. This infusion of capital, within the context of its overall enterprise-level funding, suggests a strong investor confidence in the company's therapeutic approach and market potential. Rhythm Pharmaceuticals is poised to further solidify its position as a leader in rare genetic obesity disorders, potentially bringing much-needed therapies to patients with limited options.
See full Rhythm Pharmaceuticals company page
